Abstract: Since the tyrosine phosphatase SHP-1 plays a major role in regulating T cell signaling, we investigated regulation thereof by Ser/Thr phosphorylation. We found that T cell receptor (TCR) stimulation induced fast (<1 min) and transient phosphorylation of SHP-1 S591 in both Jurkat and human peripheral blood T-cells (PBT). Phosphorylation of S591 in T-cells could be mediated artificially by a constitutive active PKC-theta construct, but the dose dependence of inhibition by PKC inhibitors indicated that PKCs were not the relevant basophilic kinase in the physiological response. S591 phosphorylation inhibited phosphatase function since a S591D mutant had lower activity than the S591A mutant. Additional evidence that S591 phosphorylation alters SHP-1 function was provided by studies of Jurkat cells stably expressing SHP-1 wild type or mutants. In those cells, S591D mutation reduced the capacity of transfected SHP-1 to inhibit TCR-induced phosphorylation of PLC-␥1. Interestingly, SHP-1 Y536 phosphorylation (previously shown to augment phosphatase activity) was also induced in PBT by TCR signal but at a much later time compared with S591 (ϳ30 min). S591 phosphorylation also altered cellular distribution of SHP-1 because: 1) SHP-1 in lipid rafts and a sheared membrane fraction was hypophosphorylated; 2) In stably transfected Jurkat cell lines, S591D mutant protein had reduced presence in both lipid raft and the sheared membrane fraction; 3) S591 phosphorylation prevented nuclear localization of a C-terminal GFP tagged SHP-1 construct. Our studies also shed light on an additional mechanism regulating SHP-1 nuclear localization, namely conformational autoinhibition. These findings highlight elegant regulation of SHP-1 by sequential phosphorylation of serine then tyrosine. J. Leukoc. Biol. 82: 000 -000; 2007.
INTRODUCTION
Phosphorylation and dephosphorylation are among the most important post-translational protein modifications, which often result in major changes in protein function. Protein kinases and phosphatases play counterbalancing roles regulating protein function in a temporally and spatially controlled fashion. SHP-1 (SH2 domain containing phosphatase 1) is a tyrosine phosphatase expressed mainly in hematopoietic cells [1, 2] . The importance of SHP-1 is highlighted by the characteristic phenotype of the SHP-1-deficient moth-eaten mice [3] . Those mice die at several weeks of age from inflammation of the lung, resulting from uncontrolled granulocyte proliferation and infiltration. They also have lymphocyte abnormalities, specifically hyperactivation of lymphocytes after antigen receptor engagement.
In T lymphocytes, SHP-1 is essential for attenuation of T cell receptor (TCR) signaling after initiation of the response [4] . Indeed, SHP-1 plays a role in the differential response to agonist/antagonist peptides [5] . Many signaling molecules downstream of TCR are targets of SHP-1-mediated dephosphorylation; each of them has to be dephosphorylated at the right time and place to allow both efficient and controlled signaling. To achieve this, SHP-1 is likely to be regulated precisely by changes of both its phosphatase activity and cellular distribution. Its phosphatase activity is known to be powerfully increased by phosphorylation of Y536 [6] . The structural basis for this up-regulation of activity has been suggested by mutational and structural studies showing that the SH2 domains of SHP-1 form extensive interaction with the catalytic domain, inhibiting its activity [7] . It has been proposed that binding of SHP-1 SH2 domains with phosphotyrosine, either intra-or intermolecularly, releases it from autoinhibition [8] . Binding of SHP-1 SH2 domain with phosphotyrosine motifs (immunoreceptor tyrosine-based inhibitory motif, ITIM; immunoreceptor tyrosine-based switch motif, ITSM) is also an important strategy of SHP-1 recruitment [9 -12] , which brings SHP-1 close to its effector molecules. On the contrary, binding of phosphorylated Y564 of SHP-1 with the SH2 domain of Lck has been shown to recruit SHP-1 to its intended target, which can be inhibited by ERK phosphorylation of lck [5] . Lipid rafts are important membrane microdomains where signaling processes take place. SHP-1 is present in lipid rafts, and its lipid raft presence is critical for its function [13] . SHP-1 lipid rafts localization depends on its C-terminal tail but not on the SH2 domains [13, 14] , but nothing is known about what can change SHP-1 lipid rafts localization.
Ser/Thr phosphorylation of SHP-1 was identified [15, 16] shortly after the identification of SHP-1 [17] . This was associated with decreased phosphatase activity, and PKC was proposed to be the relevant kinase [18] , but the exact site had not been mapped. Using algorithms developed from our studies on substrate specificity of PKC [19] , we found that S591 close to the very end of SHP-1 C-terminal tail was potentially a very good phosphorylation site for PKC or other basophilic kinase. The PKC family is a member of a much larger group of "basophilic kinases," which constitute a large group of Ser/Thr kinases that phosphorylate S/T residues in the context of a cluster of basophilic residues [20, 21] . Such clusters of basophilic residues have important functions, including membrane binding motifs or nuclear localization signals. In fact, previous studies already identified the stretch of positively charged residues around S591 in SHP-1 as a functional nuclear localization signal [22] . Phosphorylation, by neutralizing the net positive charge, is an important way of regulating those biological processes. The present study confirms our in silico prediction, and demonstrates that S591 of SHP-1 is phosphorylated following TCR stimulation. This confirms and extends a report, published during our studies, of S591 phosphorylation in platelets in response to thrombin [23] ; but the TCR-induced response appears not to be mediated by PKC. Our studies demonstrate that S591 phosphorylation inhibits phosphatase activity and that the early and transient inhibitory phase of S591 phosphorylation after TCR stimulation is followed by Y536 phosphorylation, previously shown to augment phosphatase activity. Moreover, we demonstrate that SHP-1 nuclear localization is inhibited not only by phosphorylation at this site but also by intramolecular autoinhibition.
MATERIALS AND METHODS

General
BIM I and III were purchased from EMD Biosciences (San Diego, CA, USA). 4G10 anti-phosphotyrosine mAb and polyclonal anti-SHP-1 antibody made by immunization with whole SHP-1 protein were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Monoclonal anti-SHP-1 Ab (clone 52; BD Biosciences, San Jose, CA, USA) is the product of immunization with a fusion protein containing the SHP-1 C-terminal 106 residues. Anti-SHP-1 antipeptide Ab (sc-287; Santa Cruz Biotechnology, Santa Cruz, CA, USA) is the product of immunization with a peptide containing the C-terminal 19 residues. Antibodies against pY319 of ZAP70 and T202/Y204 of MAP kinase were purchased from Cell Signaling Technologies (Danvers, MA, USA). Anti-SHP-1 pS591 antibody was made by immunization of rabbits with a phospho-peptide CDKEKSKGpSLKRKOH coupled to KLH. SHP-1 anti-pY536 is a monoclonal antibody raised in mice against pY536 by BD Biosciences. Goat anti-Mouse IRDye 680 and Goat anti-rabbit IRDye 800CW were purchased from LI-COR (Lincoln, NE, USA). All figures represent results of at least two independent experiments.
Constructs and expression
Mouse SHP-1 cDNA was cloned into Gateway expression vector with Nterminal GFP tag (pcDNA-Dest53) or C-terminal GFP tag (pDest472). Mutations (S591A, S591D, S582D, and S588D) were made with Stratagene QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). All constructs made are fully sequence-validated.
Cell culture, transfection, stimulation, and imaging HEK293T cells were grown in Dulbecco modified Eagle medium (Life Technologies, Inc., Carlsbad, CA, USA) with 10% FCS. Transfection of HEK293T cell is mediated by calcium phosphate, as described previously [24] . Jurkat cells (E6-1) were grown in 10% FCS RPMI 1640 (Life Technologies). For transfection, 1 ϫ 10 7 Jurkat cells in 0.4 ml RPMI 1640 with 20 mM HEPES were mixed with appropriate plasmids and electroporated at 310 V and 10 ms in a BTX ECM 830 electroporator. For stable transfection, the transfected cells were cultured in selection media containing 1 mg/ml G418. For stimulation, Jurkat cells were stimulated or not with CD3 mAb (clone 38.1 ascites, 1:1000) plus CD28 mAb (clone 9.3 ascites, 1:1000). For imaging, 20 h after transfection, the cells were observed using a Zeiss LSM510 confocal microscope (Carl Zeiss MicroImaging, Inc., Thornwood NY, USA) equipped with a ϫ40 Capochromat (NA 1.2) water immersion lens. Confocal images were collected with 0.11 m ϫ 0.11 m X-Y pixel sampling and optical slice thickness of 2.0 m.
SHP-1 phosphatase assay
SHP-1 protein (wild type (WT) or S591 mutants) was immunoprecipitated from transiently transfected HEK293 cell lysate by mAb against HA tag. The procedure was done without the presence of phosphatase inhibitors, and the final wash was done with phosphatase assay buffer, which contained 20 mM HEPES, 50 mM NaCl, and 5 mM DTT. The phosphatase assay on phosphotyrosine peptide was done using the phosphatase assay kit from Upstate Biotechnology and the manufacturer's recommended protocol. A fraction of the immunoprecipitated SHP-1 was blotted with HA mAb for quantification, and the phosphatase assay result was adjusted based on the quantification. A series of twofold dilution of the immunoprecipitated SHP-1 was used in phosphatase assay and Western blot analysis to make sure the amount of different constructs were comparable.
Immunoprecipitation and Western blot
For detection of S591 phosphorylation of SHP-1, Jurkat TAg cells or HEK293T cells (transfected or not) were harvested and centrifuged. The cell pellet was loosened by vortexing, and 1ϫSDS sample buffer was directly added to the pellet and mixed. After sonication to fragment DNA, the cell lysate was boiled for 5 min. For immunoprecipitation, the cells were lysed with lysis buffer: 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.4, 2 mM Na 3 VO 4 , 5 mM Na 4 P 2 O 7 , protease inhibitor cocktail tablet. The lysate was cleared by centrifugation at 14,000 rpm for 10 min. Immunoprecipitation was done with the indicated Ab and protein G agarose (Invitrogen). For Western blot analysis, immunoprecipitate or cell lysate in SDS sample buffer were separated by SDS-PAGE and transferred to nitrocellulose membrane. Detection of some of the Western blot analysis was done using the Amersham ECL kit following the manufacturer's protocol. Exposure was done either with film or with Fuji LAS-3000 imaging system. Other Western blots were analyzed using an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
Isolation of membrane fractions
For lipid raft isolation, 100 ϫ 10 at 6 Jurkat cells were lysed with 1 ml lysis buffer (1% Triton, 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, protease inhibitor cocktail tablet, 2 mM sodium orthovanadate, 5 mM sodium pyrophosphate). The lysate was put on ice for 30 min, and then it was transferred to a Dounce homogenizer and stroked 10 times with a loose-fitting pestle. The lysate was centrifuged at 500 g for 10 min. The recovered supernatant was mixed with equal volume 80% sucrose and transferred to an ultracentrifuge tube and then overlaid on top with 5 ml of 30% sucrose and 3 ml of 5% sucrose. After centrifuge at 40,000 rpm, at 4 c for 18 h, 12 even fractions (each ϳ0.8 ml) were harvested. Lipid raft distribution was detected by blotting with cholera toxin for the presence of GM1 ganglioside. Fractions 3, 4, 5, and 6 were pooled as the lipid raft fraction. Fractions 11 and 12 were pooled as the cytosolic fraction. Isolation of a sheared membrane fraction by a protocol modeled after procedures used for separation of placental microvilli (unpublished results). In brief, cells were passed repeatedly through a 27G needle. Cells that remained viable were removed by sedimentation at 2500 g for 5 min. Membrane-enriched fragments, including microvilli were recovered by sedimentation at 16000 g for 40 min.
RESULTS
S591 of SHP-1 is phosphorylated in T lymphocytes in response to TCR stimulation
Predictive algorithms can be very useful in identifying potential phosphorylation sites. But such predictions are most reliable in predicting what "class" of kinase might phosphorylate a site (e.g., basophilic) rather than exactly which kinase of that class would mediate the phosphorylation (e.g., PKC). During our in silico analysis of molecules involved in TCR signal transduction, we identified a promising site for PKC or another basophilic kinase near the C terminus of SHP-1. As an initial test of that prediction, we used a "PKC substrate antibody" (pPKC) from Cell Signaling Technology because the sequence surrounding S591 fits perfectly with the sequence pattern recognized by this antibody. We blotted SHP-1 immunoprecipitated from resting or CD3/28-stimulated Jurkat cell with the pPKC Ab. There is already some signal recognized by this antibody in SHP-1 from resting cells, but the signal in SHP-1 from CD3/28-stimulated cells were stronger, indicating CD3/28 stimulation induced phosphorylation of SHP-1, possibly at S591 (Fig. 1A) .
To confirm that S591 is the phosphorylation site on SHP-1, which is recognized by the pPKC Ab, we made SHP-1 constructs, wild-type or S591 mutated to A to prevent phosphorylation, tagged at their N terminus with GFP (N-GFP_SHP-1 and N-GFP_SHP-1 S591A). Because the sequence surrounding S591 fits the amino acid pattern recognized by PKC (or other basophilic kinase), we expected that overexpression of PKC together with the SHP-1 construct would result in phosphorylation of S591. As predicted, transfected SHP-1 was phosphorylated when cotransfected with constitutively active PKC theta (PKC theta CA) (Fig. 1B) . In contrast, the phosphorylation recognized by pPKC Ab was not observed when the S591A mutant of SHP-1 was transfected into Jurkat cells together with PKC theta CA. Control conditions show that SHP-1 transfected alone into Jurkat cells alone was not detected well by the pPKC Ab. Thus, the phosphorylation in SHP-1 that is recognized by pPKC Ab is on S591, and that site can be phosphorylated by overexpressed PKC theta.
To facilitate further study of the newly identified phosphorylation site, we made a phospho-specific Ab against S591 of SHP-1. WB with this antibody showed a pattern similar to that observed with the pPKC antibody (Fig. 1B) . Phosphorylation of transfected SHP-1 occurred only when cotransfected with PKC theta CA and was lost on the S591A mutant, indicating the specificity of the antibody. Thus SHP-1 can be phosphorylated by overexpressed constitutively active PKC theta, and the pS591 antibody specifically recognizes that phosphorylated site.
We tested the possibility that PKC was involved in TCRinduced SHP-1 S591 phosphorylation in Jurkat cells by using PKC inhibitors BIM I and BIM III. As expected, the pS591 Ab detects TCR-induced phosphorylation previously detected with the pPKC Ab (Fig. 1C) . At concentrations of 5 M or above, both BIMs inhibited S591 phosphorylation. But below 1 M neither inhibited effectively. Since the IC 50 of both inhibitors are in the low nanomolar range for PKC, the results suggest that some basophilic kinase other than PKC mediates this S591 phosphorylation.
We investigated the kinetics of S591 phosphorylation in both Jurkat cells and primary T cells ( Fig. 2A) . Anti-CD3/28 stimulation of Jurkat cells induced rapid and transient phosphorylation on S591 of SHP-1, which was strong by 1 min after stimulation and decreasing by 10 min. CD3/28-induced S591 phosphorylation in human peripheral blood T-cells (PBT) had similar kinetics to that observed in Jurkat. To study the kinetics of S591 phosphorylation more accurately, we looked at S591 phosphorylation in the time range of 5 to 60 s after stimulation of Jurkat cells and compared it with other phosphorylation events in the cells induced by TCR (Fig. 2B ). By 15 s after stimulation, S591 phosphorylation already had reached its maximum and maintained the level throughout the time range. The kinetics of S591 phosphorylation closely paralleled the early burst of tyrosine phosphorylations in T lymphocyte in response to TCR stimulation as revealed by generic anti-phospho tyrosine Ab blot. In contrast, phosphorylation of ERK was a much later event, which only began to appear at 30 s after stimulation and was still increasing at 60 s after stimulation. The result indicates S591 phosphorylation is a very early event in TCR signal transduction.
Genetic evidence that PLC-␥1 tyrosine phosphorylation is influenced by S591 phosphorylation
To determine whether S591 phosphorylation changes SHP-1 cellular function, we made stably transfected Jurkat cell lines expressing SHP-1 wild-type, S591A, and S591D mutants and assessed tyrosine phosphorylation in those cells following TCR stimulation. After 1 min of CD3/28 stimulation, multiple bands were tyrosine phosphorylated Most of the activation-induced changes in tyrosine phosphorylation were similar between transfected and untransfected cells (Fig. 3A) . The notable exception was a band at ϳ150 kDa, suggestive of PLC-␥1. In Jurkat transfected with wild-type N-GFP_SHP-1 and its S591A mutant, phosphorylation of this band was significantly decreased, but in S591D mutant-transfected Jurkat cells, phosphorylation of this band was as strong as in control Jurkat cells. Reprobing of the same cell lysate with PLC-␥1 Ab showed that PLC-␥ 1 expression was equivalent in all of the cells. To confirm the finding, PLC-␥ 1 was immunoprecipitated from equal amounts of cell lysate of control Jurkat cells and SHP-1 constructs stably transfected Jurkat cells stimulated or not with CD3/28 for 1 min (Fig. 3C) and was blotted to detect phosphotyrosine. The results confirm that PLC-␥ 1 tyrosine phosphorylation was decreased significantly in wild-type and S591A mutant stably transfected Jurkat cells, but in S591D mutant stably transfected Jurkat cells, it was as strong as in control Jurkat cells. To confirm that the change in PLC-␥ 1 phosphorylation was selective, two site-specific phosphoantibodies were also tested on the same cell lysates (Fig. 3B) . Results for pY319 of ZAP70 and pT202/Y204 of ERK, showed that these phosphorylation events were unaffected by SHP-1 transfection. Quantitative analysis of PLC-␥ 1 phosphorylation results from five experiments (Fig. 3D) clearly indicated that PLC-␥ 1 phosphorylation level in SHP-1 S591D stably transfected Jurkat cells was comparable with wild-type control Jurkat cells, but higher than SHP-1 WT-or S591A mutant-transfected Jurkat cells. Thus, SHP-1 S591 phosphorylation, mimicked by S591D mutation, can change its function.
S591 phosphorylation decreases SHP-1-mediated dephosphorylation
We investigated whether S591 phosphorylation regulates SHP-1 phosphatase activity. In the course of our study, Jones et al. [23] reported that SHP-1 S591 was phosphorylated in platelets. Their results suggested that S591 phosphorylation reduced phosphatase activity, but complexities of their assay (see Discussion) prompted us to investigate the question in alternative ways. We made SHP-1 constructs (N-terminal HA tagged), WT and S591 to A or D mutants, and compared their activity after purification of the protein from transfected HEK293T cells lysate in a time course study with pY peptide as a substrate. The results showed that although the activity of SHP-1 WT and S591A mutant was similar, S591D mutant had ϳ30% lower activity (Fig. 4) . These data indicate that phosphorylation of S591 per se regulates its ability to dephosphorylate proteins.
TCR-induced sequential phosphorylation of SHP-1 S591 and Y536 in human PBT
Because it has been shown previously that Y536 phosphorylation up-regulates SHP-1 phosphatase activity [6] in contrast to S591, which decreases its activity, we investigated the temporal relationship between S591 phosphorylation and Y536 phosphorylation of SHP-1 in human PBT. S591 phosphorylation peaked at 1 min after stimulation and then started to decline (Fig. 5 and Fig. 1 ). In contrast, Y536 phosphorylation was evident only at 3 min of stimulation and keep on increasing until at least 30 min after stimulation. The results indicated that the peak of S591 and Y536 phosphorylation are temporally separated, which serves to first decrease phosphatase activity and subsequently increase it. 
S591 mutation in N-GFP_SHP-1 changed its cellular distribution in Jurkat cells
We also investigated the possibility that S591 phosphorylation could change SHP-1 cellular distribution as another mechanism to control SHP-1 cellular function. We first investigated SHP-1 localization to lipid raft fractions of Jurkat cells. Fractions were blotted with both the pS591 Ab and a pan-SHP-1 antibody (whose binding is unaffected by the phosphorylation state of S591). To optimize comparison of phosphorylation, amounts of protein in each lane were made more comparable by loading twice as much lipid fraction as cytosolic fraction. Despite comparable loading (Fig. 6A) , phosphorylation of S591 of SHP-1 in the lipid raft fraction was much lower than that of the cytosolic fraction.
To verify that S591 phosphorylation changes SHP-1 cellular distribution, we used another strategy to enrich for plasma membrane, namely, by cell-shearing. This procedure, modeled after published procedures for enrichment of placental microvilli, leaves viable cells and generates a fraction containing ϳ1% of non-nuclear cell protein and enriched in plasma membrane plus microvilli (unpublished results). A sheared membrane fraction was made from human PBT, blotted with both SHP-1 Ab and anti-pS591 Ab, and compared with total lysate (Fig. 6B) . SHP-1 blot showed that the amount of SHP-1 in the total lysate and sheared membrane fraction were about the same, but S591 phosphorylation of SHP-1 in total lysate was much stronger than in the sheared membrane fraction.
The foregoing two approaches demonstrated SHP-1 S591 hypophosphorylation in lipid raft and sheared membrane fraction. It was important to determine whether S591 phosphorylation prevented SHP-1 lipid raft/sheared membrane distribu- tion or lipid raft/sheared membrane distribution caused SHP-1 dephosphorylation on S591. Therefore, we studied the distribution of SHP-1 WT and its S591A or S591D mutant in lipid raft and sheared membrane fraction using the stably transfected Jurkat cells described above. The results indicate that the S591A mutant of SHP-1 was more abundant both in lipid rafts (Fig. 6C ) and in the sheared membrane fraction (Fig. 6D ) compared with WT and S591D mutant of SHP-1. As an internal control, we investigated the distribution of endogenous SHP-1 in all three cell lines and found that they are very similar (data not shown). The results clearly indicate that SHP-1 S591 phosphorylation impedes its localization in the lipid and sheared membrane fractions.
Regulation of SHP-1 nuclear localization
S591 is located close to the C terminus of SHP-1, in the middle of the previously identified nuclear localization signal (NLS) of SHP-1. Since phosphorylation in the proximity of NLS is a common strategy in regulating the function of the NLS, we hypothesized that S591 phosphorylation may regulate SHP-1 nuclear localization. Pilot studies to assess localization demonstrated a dramatic effect of GFP tag position on SHP-1 cellular distribution, which has also been reported by others during this investigation [25] . When the GFP tag was fused to the N terminus of SHP-1 (N-GFP_SHP-1), the transfected fusion protein was almost exclusively cytoplasmic (Fig. 7A) . In dramatic contrast, when the GFP tag was fused to the C terminus of SHP-1 (SHP-1_C-GFP), it was almost exclusively nuclear. By Western blot analysis, we found that N-GFP-_SHP-1 was phosphorylated on S591. But phosphorylation of S591 was totally absent in SHP-1_C-GFP. So SHP-1 nuclear localization correlated with dephosphorylation of S591.
To analyze genetically the effect of S591 phosphorylation on nuclear localization, we investigated the distribution of three different SHP-1_C-GFP constructs in HEK293T cells: WT, S591A, or S591D (Fig. 7B) . Although the WT and the S591A mutant distributed mainly in the nucleus of the cells the S591D mutant distributed mainly in the cytoplasm of the cells. Analysis of constructs expressing aspartic acid mutations of other serines nearby (i.e., S582D and S588D), showed that only S591D prevented nuclear localization of SHP-1_C-GFP (Fig.  7B) .
We investigated phosphorylation per se of S591 to exclude the possibility that the effect on nuclear exclusion of the S591D mutation might not exactly mimic phosphorylation at that site. For this purpose, we took advantage of the fact that PKC theta CA can phosphorylate S591 of SHP-1 when cotransfected. As described above, HEK293T cells transfected SHP-1_C-GFP distributed almost exclusively in the nucleus of the cells. But when PKC theta CA was cotransfected, the localization of SHP-1_C-GFP became almost exclusively cytoplasmic (Fig.   Fig. 5 . TCR induces sequential SHP-1 S591 and Y536 phosphorylation. Human PBT was stimulated or not with CD3/28 Abs for various time. The cell lysate was blotted with pS591 or pY535 phospho-specific Abs. Quantitation of the optical density of the immunoblot is also shown, in which the y-axis shows phosphorylation relative to maximum observed. 
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). Western blot analysis showed that cotransfection of PKC theta CA resulted in S591 phosphorylation of SHP-1_C-GFP (cf. Figure 1B) . S591 phosphorylation per se contributed to the change in localization, because the change caused by PKCtheta was not observed with the S591A mutant. The effect of S591 phosphorylation on SHP-1 nuclear localization was further confirmed by the observation that treatment with a high concentration of the PKC inhibitor, BIM I, blocked S591 phosphorylation by cotransfected PKC theta CA and eliminated its nuclear exclusion (Fig. 7D) . Although endogenous SHP-1 localized almost exclusively in the cytoplasm, transfected SHP-1_C-GFP distributed mostly in the nucleus in Jurkat T cells as in HEK293T cells (data not shown). Thus, S591 phosphorylation blocks nuclear localization of SHP-1.
We considered the possibility that mechanisms other than S591 phosphorylation might regulate nuclear localization. We reasoned that if the nuclear localization of SHP-1 is solely regulated by S591 phosphorylation, mutating S591 to A to prevent phosphorylation in the N-GFP_SHP-1 should change its localization to nuclear. But the S591A mutant remained cytoplasmic (Fig. 8A) . The exact structure of the C-terminal tail is still unknown since the C-terminal tail is not present in the solved structure of SHP-1. We hypothesized that the Cterminal tail of SHP-1 normally interacts with another part of the phosphatase, thereby masking the NLS. In our conceptual model, the bulky GFP tag in the SHP-1_C-GFP construct prevents that intramolecular interaction of the C terminus, thereby unmasking the NLS. To provide experimental evidence for the hypothesis, we performed a limited trypsin digestion experiment, a commonly used strategy in studying the accessibility of molecular regions. The more exposed a region of the molecule is, the easier it will be to digest by trypsin. N-GFP_SHP-1 and SHP-1_C-GFP were transfected into HEK293T cells, and the cell lysate was treated with various concentration of trypsin and blotted with two anti-SHP-1 antibodies, a monoclonal antibody ("proximal") raised against the C-terminal 106 residues and a polyclonal antipeptide antibody ("distal") raised against the last 19 amino acids in C-terminal of SHP-1. SHP-1_C-GFP is especially sensitive to proteolytic loss of its GFP moiety based on molecular weight shift (Fig. 8B) and loss of reactivity with anti-GFP (not shown). The proximal and distal Abs both recognized a 65-kDa fragment, from both N-GFP_SHP-1 and SHP-1_C-GFP. That 65-kDa fragment is the size of full-length SHP-1 and has the intact C-terminal tail, so it appears to be full-length SHP-1 molecule after the GFP tag has been cleaved. In addition, there is a 60-kDa fragment that reacts only with the proximal antibody but not the distal antibody, indicating loss of the C terminus. This 60-kDa fragment is already obvious at 0.375 g/ml of trypsin treatment for C-N-GFP_SHP-1 but only appears at 0.75 g/ml of trypsin treatment for N-GFP_SHP-1. The results suggest that the Cterminal tail of SHP-1 in SHP-1_C-GFP is more exposed because of the GFP tag, but somewhat hidden in N-GFP-_SHP-1, which would explain why its NLS is not functional.
DISCUSSION
The present study demonstrates that TCR activation of lymphocytes results in rapid phosphorylation of SHP-1 S591 (Fig.  1) . This S591 phosphorylation inhibits SHP-1 phosphatase activity (measured on a phosphotyrosine peptide substrate, Fig.  4) . Notably, however, this phosphorylation is transient and is followed by a wave of tyrosine phosphorylation on Y536 (Fig.  5) . Thus, SHP-1 undergoes a rapid decrease in phosphatase activity in the first several minutes and thereafter an increase in activity. Moreover, phosphorylation of SHP-1 S591 regulates its localization, decreasing membrane localization and preventing nuclear localization. This discussion focuses on the following issues: 1) the basophilic site and candidate kinases; 2) regulation of phosphatase activity; 3) regulation of localization; and 4) a conceptual model of the role of S591 phosphorylation for TCR activation S591 is an ideal site for phosphorylation by a basophilic kinase. First, by virtue of being close to the terminus of the molecule, it is likely to be relatively accessible conformationally. This conformational accessibility is also facilitated by its hydrophilic composition (KEKSKG-S-LKRK-Cterm). Second, the surrounding sequence includes six basic residues in a stretch of 11 amino acids. This gives the region a very strong net positive charge at physiological pH, which is the major prerequisite for recognition by basophilic kinases. Our in silico analysis of SHP-1 (data not shown) indicates that although there are two other potential basophilic phosphorylation sites in SHP-1 (S26 and S32), S591 is the most favorable and likely to be the primary one responsible for the early reports of SHP-1 serine phosphorylation [15, 18, 26] . What is the relevant kinase(s)? Two reports link SHP-1 phosphorylation to PKC: an early report in which the site was not identified [18] and the recent report of S591 phosphorylation in platelets [23] . In contrast, two of our findings in T-cells do not support a physiological role for PKC phosphorylation following TCR stimulation. First, inhibition by BIMs is not as efficient as would be expected to PKCs. Second, constitutive active PKC-theta phosphorylated transfected GFP-tagged SHP-1 but not endogenous SHP-1 (data not shown). Specifically, the inhibitors BIM I and BIM III are both inhibitors for PKC at low nanomolar concentration in vitro (IC 50 , 10-30 nM). In PKC-mediated cellular processes, concentrations as low as 100-500 nM are sufficient to achieve strong inhibition (see Supplemental Fig. 1 ). But instead, concentrations of 5-10 M of BIM I and BIM III were needed to completely inhibit TCR-induced S591 phosphorylation (Fig. 1) . Moreover, kinases other than PKC could very well be inhibited too at those concentrations (for example, PKA, IC 50 , 500 nM; GSK-3, IC 50 , 360 nM per EMD/Calbiochem; see also [27] ). On the basis of those results, PKCs at least are not the only kinase(s) phosphorylating S591 in T lymphocytes. It should be noted that the previous reports of PKC involvement showed partial inhibition at relatively high concentrations of BIM I in intact cells {2 M in [18] and 5 M in [23] }. It should also be noted that although PKC can phosphorylate SHP-1 in vitro [18] , such an in vitro assay is no basis for concluding the in vivo relevance, since many basophilic kinases phosphorylate substrates in vitro that are not in vivo substrates. These complexities leave open the possibility that even in the cell systems previously studied, PKC may not be the relevant kinase family.
Our studies and two others support the conclusion that serine phosphorylation of SHP-1 inhibits its phosphatase activity. The most direct evidence for S591 involvement in phosphatase inhibition is provided by the present study, in which the S581D mutation was demonstrated to reduce SHP-1 phosphatase activity by ϳ30% (Fig. 4) . Because replacement of serine with aspartic acid is only a partial mimic of phosphorylation, it is quite likely that phosphorylation of this residue will result in a much larger inhibition. Downey and co-workers showed that phosphorylation of SHP-1 by PKC inhibited its phosphatase activity [18] . These results do not directly implicate S591 (since the residue was not identified in that study) but are consistent with its involvement. Moreover, both Poole and Downey used another approach, in which they demonstrated that SHP-1 in vitro phosphatase activity was increased by 2-5 M BIM inhibition in intact cells [23] . Again, these results do not directly implicate S591 but are consistent with its involvement.
The present studies also demonstrate that phosphorylation of S591 profoundly inhibits nuclear translocation. This is demonstrated both genetically, in the S591D mutant (Fig. 7B) , and by intracellular phosphorylation by a basophilic kinase (Fig.  7D ). S591 localizes right in the middle of the identified SHP-1 NLS, which contains a series of positively charged residues ( [22, 28] . The regulation of the NLS by S591 phosphorylation is consistent both with the concept that phosphorylation changes the positive charge required in a NLS and with other molecules in which phosphorylation impairs NLS-based nuclear localization [e.g., 29, 30] . In addition to this regulation, another powerful mechanism inhibits nuclear localization in T-cells; our studies suggest that this mechanism relates to conformational autoinhibition (Fig. 8) . Our findings that Cterminal GFP tagging results in nuclear translocation in T-cells are consistent with recent findings in fibroblast-derived cell lines [25] . Our studies with endogenous SHP-1 in Jurkat cells and primary T-cells indicate that it is localized in cytoplasm both before and after TCR stimulation (consistent with the localization observed for SHP-1 tagged N-terminally with either HA peptide or GFP), Thus we have no evidence that phosphorylation is important in excluding SHP-1 from the nucleus in early T cell signal transduction. However, SHP-1 has been clearly demonstrated in the nucleus in numerous contexts with other cell types. For example, SHP-1 is found in the nucleus in epithelial cells where it appears to regulate expression of several genes [31] ; it is also in the nucleus in ES cells [32] . Further studies will be required to elucidate the cell types and the signaling pathway in which phosphorylationmediated nuclear inhibition of SHP-1 plays an important physiological role.
How does S591 phosphorylation alter TCR-mediated signaling? Our studies demonstrate that S591D is specifically unable to regulate PLC-␥1 phosphorylation (Fig. 3) . Although such overexpression studies clearly demonstrate regulation of SHP-1 function by a genetic mimic of phosphorylation, they cannot address the fine regulation necessary in receptor-mediated phosphorylation. We estimate that rapid TCR-induced serine phosphorylation of SHP-1 (Fig. 2) occurs on ϳ5-20% of the total SHP-1 pool (based on comparisons with EL-4 cells, which have much stronger S591 phosphorylation, data not shown). The SHP-1, which is phosphorylated on S591, will have diminished phosphatase activity (Fig. 4) and decreased capacity to localize to membrane (Fig. 6) . SHP-1 exists in many distinct pools complexed to other molecules [5, [32] [33] [34] . Differential phosphorylation of S591 in such pools, which may not be in rapid equilibrium with each other, would confer different functional properties on SHP-1 in such pools. Moreover, our studies demonstrate that early S591 phosphorylation (which decreases the phosphatase activity in that pool) is followed temporally by Y536 phosphorylation, which would be expected to increase its phosphatase activity. It is plausible that this Y536 phosphorylation is likewise in a distinct pool that contributes to the termination of acute TCR signaling. This interplay of positive and negative regulation by phosphorylation illustrates the elegant combinatorial control of SHP-1 function.
